Antizol

Antizol®

Fomepizole A proprietary injectable antidote for ethylene glycol–antifreeze poisoning. See Antifreeze.
References in periodicals archive ?
The company, which focuses on treatments for niche psychiatric and neurological conditions, has several products on the market, including narcolepsy drug Xyrem (which is also in clinical trials for fibromyalgia) and Antizol, an antidote for ethylene glycol and methanol poisoning.
These include fomepizole injection, a generic equivalent of Antizol, in the U.S.
Antizol and Cystadane revenue for the quarter was $3.6 million, an increase of approximately 81 percent from $2.0 million for the same period last year.
We were very pleased with the strong performance of Antizol which continues to be stocked by more hospitals and is currently used to treat approximately two-thirds of the reported ethylene glycol and methanol poisonings in the United States."
A new antidote, fomepizole (Antizol), a competitive inhibitor of alcohol dehydrogenase (enzyme responsible for the initial step in both methanol and ethylene glycol conversion), is FDA-approved for the treatment of ethylene glycol (46) and methanol poisoning (47).
Marketed as Antizol, this orphan medication was first approved for ethylene glycol exposure in 1997 and was more recently approved for toxic ingestion of methanol, a common ingredient in windshield wiper fluid and cleaning products.
Antizol and Cystadane revenue was $2.8 million for the quarter ended June 30, 2004 an increase of approximately 33 percent from $2.1 million for the same period in the prior year.
"Xyrem prescribing grew well during the first quarter, especially in the second half of the quarter and sales of our antidote product Antizol were very strong.